Evidence map›Paper›PMID 33542673›Full record

ArticleJournal of healthcare leadership2021

A Methodology for Mapping the Patient Journey for Noncommunicable Diseases in Low- and Middle-Income Countries.

Tanaya Bharatan, Ratna Devi, Pai-Hui Huang, Afzal Javed, Barrett Jeffers, Peter Lansberg, Kaveri Sidhu, Kannan Subramaniam

Abstract read
In one paragraph

Article in Journal of healthcare leadership, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Patient journey for hypertension and dyslipidemia in Saudi Arabia: highlighting the evidence gaps.Archives of public health = Archives belges de sante publique · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tanaya BharatanResearch Development & Medical, Upjohn Division, Pfizer Ltd, Mumbai, India.ORCID 0000-0002-9153-0706
Ratna DeviExecutive Office, Daksham A Health and Education, Gurgaon, India.ORCID 0000-0002-9817-3836
Pai-Hui HuangMedical Affairs, Viatris, Taipei, Taiwan.ORCID 0000-0001-6782-8011
Afzal JavedWarwick Medical School, University of Warwick, Warwick, UK.
Barrett JeffersMedical Affairs, Viatris Inc, New York, NY, USA.
Peter LansbergDepartment of Pediatrics, University Medical Center, Groningen, the Netherlands.ORCID 0000-0003-2539-239X
Kaveri SidhuResearch Development & Medical, Upjohn Division, Pfizer Ltd, Mumbai, India.ORCID 0000-0001-5689-9973
Kannan SubramaniamMedical Affairs, Viatris | Mylan New Zealand Ltd, Auckland, New Zealand.ORCID 0000-0001-5551-4103

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noncommunicable diseases (NCDs) are responsible for 71% of all worldwide mortality each year, and have an exceptionally large impact in low- and middle-income countries (LMICs). However, there is often a lack of local data from these countries to inform practice and policy improvements. Generating locally contextualized evidence base for NCDs that can help identify gaps, aid decision-making and improve patient care in LMICs needs an innovative approach. The approach used in Mapping the Patient Journey Towards Actionable Beyond the Pill Solutions (MAPS) is designed to quantitatively map different stages of the patient journey in four critical NCDs, ie, hypertension, dyslipidemia, depression, and pain (chronic and neuropathic) across selected LMICs in Africa, the Middle East, South East Asia, and Latin America. The key touchpoints along the patient journey include awareness, screening, diagnosis, treatment, adherence, and control or remission. MAPS employs an evidence mapping methodology that follows a three-step semi-systematic review: 1) systematic peer-reviewed database search; 2) unstructured searches of local or real-world data; and 3) expert opinion. Evidence generation and visualization is based on locally validated and deduplicated data published over the last 10 years. This approach will be the first to provide quantitative mapping of the different stages of the patient journey for selected NCDs in LMICs. By focusing on local, patient-centric data, the goal of the MAPS initiative is to address and prioritize local research and knowledge gaps, then contribute to evidence-based, high-quality, and affordable advances in the management of NCDs in LMICs. This will ultimately improve patient outcomes and contribute towards the achievement of global NCD targets.

Indexed as

decision-makingevidence mappinglow- and middle-income countriesnoncommunicable diseasespatient journey

Identifiers

PMID33542673
PMCPMC7853412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.